Electra Therapeutics

Q3 FY2026 EarningsQ3 FY26 results for ETRA showed a net loss of $23.9M, which was narrower than the $27.5M loss expected by consensus, primarily driven by higher-than-expected interest income following a $350M IPO. Operating loss of $25.1M was 10.3% wider than the expected $28.0M as R&D and G&A expenses scaled to support the global registrational program for ipsoprubart. Diluted GAAP EPS of -$3.47 significantly missed the -$0.97 consensus, largely due to a lower-than-anticipated share count weighting post-IPO rather than operational underperformance. Management confirmed a strong cash runway extending into 2029.